Devices and methods for detection of biomarkers

Abstract

Devices for detecting biomarkers in a sample and methods for detecting such biomarkers are discussed. The biomarkers may be associated with a particular disease such as breast cancer or another health condition. The devices may contain a disc including a plurality of microfluidic channels extending in a radial direction of the disc, the microfluidic channels pre-loaded with a plurality of capture molecules specific to at least one biomarker. The methods may include introducing a fluid sample into at least one microfluidic channel of a disc, rotating the disc, such that the fluid sample flows radially outward through the at least one microfluidic channel to combine with capture molecules specific to at least one biomarker, and detecting a signal from the disc indicative of a presence of the at least one biomarker contained in the fluid sample.

What is claimed is: 
     
         1 . A device comprising:
 a disc including a plurality of microfluidic channels extending in a radial direction of the disc, the microfluidic channels comprising a plurality of capture molecules specific to at least one biomarker, wherein each capture molecule of the plurality of capture molecules is attached to a particle.   
     
     
         2 . The device of  claim 1 , wherein the plurality of microfluidic channels comprises a first channel including a plurality of first capture molecules specific to a first biomarker and a second channel including a plurality of second capture molecules specific to a second biomarker different from the first biomarker. 
     
     
         3 . The device of  claim 2 , wherein the disc includes from 12 to 60 microfluidic channels. 
     
     
         4 . The device of  claim 1 , wherein each capture molecule is attached to a microbead having an average diameter ranging from 100 nm to 10 μm. 
     
     
         5 . The device of  claim 4 , wherein each capture molecule is attached to a microbead having an average diameter of about 1 μm. 
     
     
         6 . The device of  claim 1 , wherein each capture molecule of the plurality of capture molecules comprises an antibody. 
     
     
         7 . The device of  claim 1 , wherein the plurality of capture molecules includes capture molecules specific for biomarkers chosen from human estrogen receptor 2 (Her-2), matrix metallopeptidase-2 (MMP-2), cancer antigen 15-3 (CA 15-3), vascular endothelial growth factor (VEGF), tumor protein p53 (p53), cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), or serum estrogen receptor (SER) or osteopontin (OPN). 
     
     
         8 . The device of  claim 1 , wherein the plurality of capture molecules includes at least one antibody chosen from antibodies Clone 191924, Clone 36006.211, Clone M8071022, or Clone 190312. 
     
     
         9 . The device of  claim 1 , further comprising a power source and a detector, wherein the detector is configured to detect fluorescence or chemiluminescence. 
     
     
         10 . The device of  claim 1 , wherein the disc comprises at least one sample inlet configured to separate plasma from whole blood. 
     
     
         11 . (canceled) 
     
     
         12 . A method of detection of biomarkers using the device, comprising:
 introducing a fluid sample into at least one microfluidic channel of the disc;   rotating the disc, such that the fluid sample flows radially outward through the at least one microfluidic channel to combine with at least one capture molecule of the plurality of capture molecules; and   detecting a signal from the disc indicative of a presence of at least one biomarker of the fluid sample.   
     
     
         13 . The method of  claim 12 , wherein the fluid sample comprises a plurality of biomarkers associated with a health condition. 
     
     
         14 . The method of  claim 13 , wherein the health condition is breast cancer. 
     
     
         15 . The method of as in  claims 12 , wherein the fluid sample comprises at least one biomarker chosen from human estrogen receptor 2 (Her-2), matrix metallopeptidase-2 (MMP-2), cancer antigen 15-3 (CA 15-3), vascular endothelial growth factor (VEGF), osteopontin (OPN), tumor protein p53 (p53), cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), or serum estrogen receptor (SER). 
     
     
         16 . The method of as in  claim 12 , wherein the plurality of capture molecules includes capture molecules specific for biomarkers associated with breast cancer. 
     
     
         17 . The method of as in  claim 12 , wherein the plurality of capture molecules includes capture molecules specific for at least one biomarker chosen from human estrogen receptor 2 (Her-2), matrix metallopeptidase-2 (MMP-2), cancer antigen 15-3 (CA 15-3), vascular endothelial growth factor (VEGF), osteopontin (OPN), tumor protein p53 (p53), cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), or serum estrogen receptor (SER).